(Reuters) -Indian pharmaceutical stocks fell 1.7% on Wednesday after U.S. President Donald Trump reiterated plans to announce a “major” tariff on all pharmaceutical imports.
U.S. accounts for a third of India’s overall pharma exports.
Trump also threatened the duties on Friday, after his first set of reciprocal tariffs earlier last week exempted pharma products — a change in stance that had prompted a wild swing in pharma stocks.
On the day, all twenty constituents of the pharma index were lower, with the index dragging down the benchmark Nifty 50 by about 0.52% as of 9:20 a.m. IST.
Gland Pharma, Lupin and Zydus Lifesciences were the top losers by percentage, down between 3% and 5%.
Sun Pharma and Cipla, the top constituents by weight, fell 1.69% and 1.87%, respectively.
India’s pharma exports to the U.S. mostly comprise generics, or cheaper versions of popular drugs. These currently attract almost no U.S. levies, while India imposes about 10% tax on U.S. pharma imports, according to industry experts.
The pharma index has fallen 14.4% this year.
(Reporting by Kashish Tandon and Ananta Agarwal in Bengaluru; Editing by Savio D’Souza)
Comments